Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities.

TitleProteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities.
Publication TypeJournal Article
Year of Publication2011
AuthorsMiller, MA, Barkal, L, Jeng, K, Herrlich, A, Moss, M, Griffith, LG, Lauffenburger, DA
JournalIntegr Biol (Camb)
Date Published2011 Apr
KeywordsADAM Proteins, Algorithms, Animals, Biocatalysis, Cell Line, Cell Line, Tumor, Computational Biology, Computer Simulation, Culture Media, Conditioned, Embryo, Mammalian, Enzyme Assays, Fibroblasts, Fluorescence Resonance Energy Transfer, Fluorescent Dyes, Humans, Ionomycin, Kinetics, Matrix Metalloproteinase Inhibitors, Matrix Metalloproteinases, Mice, Mice, Knockout, Models, Chemical, Peptides, Protease Inhibitors, Recombinant Proteins, Signal Processing, Computer-Assisted, Substrate Specificity, Tetradecanoylphorbol Acetate

Matrix metalloproteinases (MMPs) and A Disintegrin and Metalloproteinases (ADAMs) are two related protease families that play key roles in matrix remodeling and growth factor ligand shedding. Directly ascertaining the proteolytic activities of particular MMPs and ADAMs in physiological environments in a non-invasive, real-time, multiplex manner remains a challenge. This work describes Proteolytic Activity Matrix Analysis (PrAMA), an integrated experimental measurement and mathematical analysis framework for simultaneously determining the activities of particular enzymes in complex mixtures of MMPs and ADAMs. The PrAMA method interprets dynamic signals from panels of moderately specific FRET-based polypeptide protease substrates to deduce a profile of specific MMP and ADAM proteolytic activities. Deconvolution of signals from complex mixtures of proteases is accomplished using prior data on individual MMP/ADAM cleavage signatures for the substrate panel measured with purified enzymes. We first validate PrAMA inference using a compendium of roughly 4000 measurements involving known mixtures of purified enzymes and substrates, and then demonstrate application to the live-cell response of wildtype, ADAM10-/-, and ADAM17-/- fibroblasts to phorbol ester and ionomycin stimulation. Results indicate PrAMA can distinguish closely related enzymes from each other with high accuracy, even in the presence of unknown background proteolytic activity. PrAMA offers a valuable tool for applications ranging from live-cell in vitro assays to high-throughput inhibitor screening with complex enzyme mixtures. Moreover, our approach may extend to other families of proteases, such as caspases and cathepsins, that also can lack highly-specific substrates.

Alternate JournalIntegr Biol (Camb)
PubMed ID21180771
PubMed Central IDPMC3173501
Grant ListR01 EB010246 / EB / NIBIB NIH HHS / United States
R01 EB010246-04 / EB / NIBIB NIH HHS / United States
R01 GM081336-04 / GM / NIGMS NIH HHS / United States
R01-EB010246 / EB / NIBIB NIH HHS / United States
R01-GM081336 / GM / NIGMS NIH HHS / United States
U54 CA112967-07 / CA / NCI NIH HHS / United States
U54CA149233 / CA / NCI NIH HHS / United States